Stock Analysis of Burning Rock Biotech Ltd (BNR) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code BNR
Close 8.30
Change 0.270 / 3.36 %
Volume 6594.00
Vol Change 749.00 / 12.81 %
IndustryDiagnostics & Research
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bullish
Growth Index Low Growth Stock
Value Index Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Burning Rock Biotech Ltd
PE (TTM)

-1.35

Very Poor
Price / Book

0.963

Very Good
Price / Sales

1.65

Good
Piotroski F Score

6.0

Good
Market Cap

85147.21 K

Enterprise Value

-521314.79 K

ROA (TTM)

-52.60

Very Poor
ROE (TTM)

-71.45

Very Poor
Net Margin (TTM)

-122.22

Very Poor
Revenue

0.826 %

558587 K
Net Profit

27.13 %

-707701.00 K
Debt to Equity

0.0112

Excellent
Altman Z Score

-6.42

Very Poor
Quick Ratio

3.09

Very Good
Cash Ratio

2.34

Good


Highs/Lows of Burning Rock Biotech Ltd
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.793 946.66 % 1.54 % 8.990.790415-May-2414-May-24
Two Week0.807 928.50 % 3.42 % 8.990.760115-May-2408-May-24
One Month0.8 937.50 % 5.60 % 8.990.715-May-2419-Apr-24
Three Month0.8125 921.54 % 5.95 % 8.990.572215-May-2414-Mar-24
Six Months0.9 822.22 % 17.48 % 8.990.572215-May-2414-Mar-24
One year2.79 197.49 % 27.52 % 8.990.572215-May-2414-Mar-24
Two year3.22 157.76 % 29.70 % 8.990.572215-May-2414-Mar-24


Technical View of Burning Rock Biotech Ltd
RSI

95.62

Mild Bearish
MACD

1.40

Mild Bullish
ADX

29.46

Bullish
Super Trend

5.71

Bullish
Williams %R

-8.35

Mild Bearish
CCI

224.40

Mild Bearish


EMA 5

6.01

Bullish
EMA 15

3.23

Strong Bullish
EMA 50

1.63

Mild Bullish
EMA 100

1.27

Strong Bullish
SMA 100

1.04

Mild Bullish
SMA 200

1.05

Strong Bullish
SMA 5 / 20

5.23 / 1.91

Strong Bullish
SMA 15 / 50

2.27 / 1.21

Strong Bullish
SMA 50 / 200

1.21 / 1.05

Strong Bullish




Charts of Burning Rock Biotech Ltd


Returns of Burning Rock Biotech Ltd with Peers
Period / StockBNRBDSXGTHACRSSPRO
1 Week946.66%-0.316%0.374%1.71%-3.05%
1 Mth937.50%30.17%3.21%-3.25%6.00%
3 Mth921.54%6.42%8.78%0%3.92%
6mth822.22%10.14%68.66%24.70%33.61%
1 Year197.49%30.17%34.17%-85.68%-12.64%
2 Year157.76%-7.35%-54.05%-90.34%-3.64%
5 Years----78.90%-86.75%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Burning Rock Biotech Ltd with Peers
Ratio / StockBNRBDSXGTHACRSSPRO
PE-1.35-2.94-0.197-817.77895.60
P/B0.963-143.890.174389.01278.38
ROA-52.60-54.53-57.04-36.6117.50
ROE-71.450-88.89-47.5731.08
Debt To Equity0.01127.760.2530.00270.0161
Revenue558587 K
0.826 % 		44026.00 K
15.22 % 		650706 K
22.32 % 		31249.00 K
5.03 % 		76194.00 K
42.39 %
Net Income-707701.00 K
27.13 % 		-63345.00 K
3.21 % 		-808403.00 K
62.91 % 		-88481.00 K
1.81 % 		-1614.00 K
96.52 %


Technicals of Burning Rock Biotech Ltd with Peers
Technical / StockBNRBDSXGTHACRSSPRO-
ADX29.4622.8537.0213.2921.99
CMF-0.2160.589-0.1360.0373-0.235
MFI43.6668.2888.3250.3061.31
RSI95.6266.0570.4445.5049.58
MACD Abv SignalTrueTrueTrueFalseTrue
Price Above 50 MATrueTrueTrueFalseFalse-
Price Above 200 MATrueTrueTrueFalseTrue-


About : Burning Rock Biotech Ltd

Address : No. 5, Xingdao Ring Road North, Guangzhou, China, 510005
Tel : 86 20 3403 7871
URL : https://www.brbiotech.com
Code : BNR, ISIN : US12233L1070, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 12_Jun_2020
Employee Count : 786

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products. In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.


Note : All Data Generated at the End of Trading Hours (EOD Data)